地佐辛注射液致静脉血栓1例分析

doi:10.19803/j.1672-8629.2021.08.21

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 793-794.
DOI: 10.19803/j.1672-8629.2021.08.21

地佐辛注射液致静脉血栓1例分析

何艳, 张锦文^*

华中科技大学同济医学院附属同济医院药学部,湖北武汉 430030

收稿日期:2020-01-13 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*张锦文,女,博士,副主任药师,临床药学。E-mail：75687455@qq.com
作者简介:何艳,女,博士,主管药师,临床药学。

Thrombocytopenic Purpura Induced by Dezocine

HE Yan, ZHANG Jinwen^*

Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei 430030, China

Received:2020-01-13 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 目的分析1例地佐辛注射液致静脉血栓的案例及相关文献,为临床合理用药提供参考。方法结合本例罕见的地佐辛不良反应报告,检索国内外地佐辛注射液不良反应相关文献,分析其发生机制。结果地佐辛注射液致静脉血栓的发生机制可能为药物对血管内皮细胞的损伤,导致血液成分改变和血流动力学异常。相关严重药品不良反应报道较少,有少量过敏性休克报道。结论合理使用地佐辛注射液,生产企业应进一步监测其风险,并修订和完善药品说明书相关内容,保障临床用药安全。

关键词: 地佐辛注射液, 静脉血栓, 凝血功能异常, 药品不良反应

Abstract: Objective To analyse a case of vein thrombosis induced by dezocin injection and related literatures, in order to provide references for clinical rational use of dezocin injection. Methods Based on the rare case report, the domestic and foreign reports of adverse reactions caused by dezocin before December 2019 were searched and analyzed. Results The mechanism of thromboembolism induced by dezocine in this case might be injury of endothelial cells, the change of blood components and hemodynamic abnormality. Serious adverse drug reactions reported less, which included a small amount of anaphylactic shock reports. Conclusion For the rational use of dezocine injection, the manufacturer should further monitor its risks, and revise and improve the relevant contents of the drug insert to ensure the safety of clinical medication.

Key words: dezocine, vein thrombosis, coagulant function abnormality, adverse drug reactions

中图分类号:

R917

何艳, 张锦文. 地佐辛注射液致静脉血栓1例分析[J]. 中国药物警戒, 2021, 18(8): 793-794.

HE Yan, ZHANG Jinwen. Thrombocytopenic Purpura Induced by Dezocine[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 793-794.

参考文献

[1] Tang H, Wu N, Zhang W, et al.Investigation and analysis of clinical application of dezocine and evaluation of rational drug use[J]. Chinese Medicine(中国医药), 2019, 8(14):1241-1244.
[2] Xu PY.Analysis and evaluation of adverse reactions of dezocine injection[J]. Modern Medicine and Health(现代医药卫生), 2018,22(34): 3547-3549.
[3] Yan DQ, Tang YM.Analysis of 73 cases of adverse reactions of dezocine injection[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2014, 22(5): 465-467.
[4] Yu DD, Sun J, Li M, et al.Analysis of 1290 ADR/ADE cases caused by dezocine injection[J]. Chinese Pharmacy(中国药房), 2017, 26(28): 3650-3653.
[5] Fan BC.Analysis of 80 cases of adverse reactions caused by dezocine injection in orthopedics department of our hospital[J]. Chinese Pharmacy(中国药房), 2015, 26(32): 4521-4522.
[6] Qiu ZH, Ji HY, Li XM, et al.One case of mydriasis caused by sudden withdrawal of dezocine[J]. Medical guide(医药导报). 2020, 39(4):577-578.
[7] Ke XR, Wang XF.Analysis of 260 cases of adverse reactions induced by intravenous dezocine[J]. Taiwan Pharmaceutical Journal(海峡药学杂志), 2012, 10(24):271.
[8] Locniskar A, Greenblatt DJ, Zinny MA.Pharmacokineticsof dezocine, a new analgesic:effect of dose and route of administration[J]. Eur J Clin Pharmacol, 1986, 30(1):121-123.
[9] Wilson JM, Cohen RI, Kezer EA, et al.Single- and multiple- dose pharmacokinetics of dezocine in patients with acute or chronic pain[J]. J Clin Pharmacol, 2013, 35(4): 398-403.
[10] O’Brien JJ, Benfield P, Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy[J]. Drugs, 1989, 38(2): 226-248.
[11] Liu R, Huang XP, Yeliseev A, et al.Novel molecular targets of dezocine and their clinical implications[J]. Anesthesiology, 2014, 120(3): 714-723.
[12] Zheng FY, Wu Y, Rao YF, et al.The role and case analysis of Naranjo assessment scale in the evaluation of adverse drug reactions[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8):650-652.
[13] Yang WJ, Xu X.Drug induced thromboembolism[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2014, 16(1): 35-38.
[14] Meng SL.Analysis of adverse reactions of dezocine injection[J]. Clinical Rational Drug Use(临床合理用药), 2020, 13(1): 14.
[15] He XW, Gan JC.Clinical and pathological analysis of purpura drug eruption[J]. Chinese Journal of Dermatology and Venereology(中国皮肤性病学杂志), 2002, 16(3): 161-163.

地佐辛注射液致静脉血栓1例分析

Thrombocytopenic Purpura Induced by Dezocine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.